ABOS
Acumen Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
0.21
close · 2026-10-30
value
1
cheaper than peers1
quality
11
stronger fundamentals11
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.44× | 98 |
| earnings yield, 2 years ago | -514.0% | 5 |
| earnings yield, 3 years ago | -504.5% | 3 |
| cash flow yield, 3 years ago | -232.4% | 3 |
| cash flow yield, 2 years ago | -283.5% | 2 |
| earnings yield, latest year | -951.9% | 0 |
| earnings yield, 1 year ago | -813.9% | 0 |
| cash flow yield, 1 year ago | -567.5% | 0 |
| cash flow yield, latest year | -760.9% | 0 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -120.5% | 22 |
| debt to equity | 55.3% | 13 |
3 of 4 measures available
Facts
| market cap | $15M |
| free cash flow | -$56.5M |
| employees | 60 |
| first trade | 2021-07-01 |
| next earnings | 2026-10-26 |
| fundamentals updated | 2026-10-26 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -2.00 | -1.71 | -1.08 | -1.06 | not reported |
| free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M | not reported |
| net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | -$460,000 | $1.6M | -$1.4M | not reported | -$81.2M |